Literature DB >> 33968494

Alemtuzumab and Fatal Myocarditis.

Neil J Scolding1, Hiam Ali1, Mary Sheppard1, Andre R Simon1.   

Abstract

Entities:  

Year:  2021        PMID: 33968494      PMCID: PMC8101301          DOI: 10.1212/CPJ.0000000000000772

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN: 2163-0402


× No keyword cloud information.
  5 in total

1.  Alemtuzumab as a novel treatment for refractory giant cell myocarditis after heart transplantation.

Authors:  Jonathan D W Evans; Stephen J Pettit; Martin Goddard; Clive Lewis; Jayan K Parameshwar
Journal:  J Heart Lung Transplant       Date:  2015-10-08       Impact factor: 10.247

2.  Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy.

Authors:  Khashayar Esfahani; Najwa Buhlaiga; Paméla Thébault; Réjean Lapointe; Nathalie A Johnson; Wilson H Miller
Journal:  N Engl J Med       Date:  2019-06-13       Impact factor: 91.245

3.  Immune checkpoint inhibitor myocarditis.

Authors:  Jayant Raikhelkar; Nir Uriel
Journal:  Curr Opin Cardiol       Date:  2019-05       Impact factor: 2.161

4.  Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab.

Authors:  Alexandre Reuben; Mariana Petaccia de Macedo; Jennifer McQuade; Aron Joon; Zhiyong Ren; Tiffany Calderone; Brandy Conner; Khalida Wani; Zachary A Cooper; Hussein Tawbi; Michael T Tetzlaff; Robert F Padera; Jean-Bernard Durand; Alexander J Lazar; Jennifer A Wargo; Michael A Davies
Journal:  Oncoimmunology       Date:  2017-08-08       Impact factor: 8.110

Review 5.  Alemtuzumab as Treatment for Multiple Sclerosis.

Authors:  Serafeim Katsavos; Alasdair Coles
Journal:  Cold Spring Harb Perspect Med       Date:  2018-10-01       Impact factor: 6.915

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.